Review
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 10, 2016; 7(9): 189-197
Published online May 10, 2016. doi: 10.4239/wjd.v7.i9.189
Neuroendocrine hormone amylin in diabetes
Xiao-Xi Zhang, Yan-Hong Pan, Yan-Mei Huang, Hai-Lu Zhao
Xiao-Xi Zhang, Yan-Hong Pan, Yan-Mei Huang, Hai-Lu Zhao, Centre of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin 541004, Guangxi Zhuang Autonomous Region, China
Xiao-Xi Zhang, Hai-Lu Zhao, Institute of Basic Medical Science, College of Basic Medical Science, Guilin Medical University, Guilin 541004, Guangxi Zhuang Autonomous Region, China
Author contributions: Zhang XX performed the majority of the writing, prepared the figures and tables; Pan YH performed data accusation and writing; Huang YM provided the information of tables of the paper; Zhao HL designed the outline and coordinated the writing of the paper.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hai-Lu Zhao, MD, PhD, Professor, Director, Centre of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Huan Cheng North 2nd Road 109, Guilin 541004, Guangxi Zhuang Autonomous Region, China. zhaohailu9@126.com
Telephone: +86-773-5805803 Fax: +86-773-5895805
Received: January 6, 2016
Peer-review started: January 9, 2016
First decision: March 1, 2016
Revised: March 16, 2016
Accepted: April 5, 2016
Article in press: April 6, 2016
Published online: May 10, 2016
Core Tip

Core tip: This is a systematic review to describe amylin as a neuroendocrine hormone. Besides the glucose homeostasis and cytotoxicity of amylin, we tried to perform that the S20G mutation of human amylin is also minor in the pathogenesis of diabetes. In addition to the metabolic effects, human amylin may have impact on autoimmunity, implicating a potential as the immunosuppressor to improve autoimmunity conditions in the future therapy of diabetes, allergic diseases and immune rejection.